Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Autologous Fat Grafting vs DIEP flap for reconstructed breast after radiation

Official title: Autologous Fat Grafting for Total Breast Reconstruction in Irradiated Patients

Run by Maastricht University Medical Center · NCT07641985 · Data updated 2026-11-12

This study tests whether autologous fat transfer can provide similar satisfaction and safety to the DIEP flap procedure for women needing breast reconstruction after mastectomy and radiation.

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment280 (estimated)
SponsorMaastricht University Medical Center
Academic / other
Drugs / interventionschemotherapy, radiation
Locations1 site (Maastricht, Limburg)
StatusRecruiting
StartedJuly 1, 2026
Main results expectedJuly 1, 2032
Study endsJuly 1, 2032
Registry record updatedAugust 21, 2026
Trial IDNCT07641985 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women over 18 with a history of breast cancer treated by mastectomy and post-mastectomy chest wall radiotherapy, who desire autologous reconstruction and can tolerate randomization between AFT and DIEP.

Probably not a fit

Patients who have insufficient donor tissue for AFT or contraindications to either procedure may not benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this study, researchers compare autologous fat transfer (AFT) with the DIEP flap method for breast reconstruction in irradiated patients post-mastectomy. The trial will look at patient satisfaction, quality of life, complication rates, and cost-effectiveness between the two approaches. Participants can be randomized to receive either AFT or DIEP flap and will be followed to assess non-inferiority in satisfaction at 12 months after final operation, along with safety and oncologic considerations. The investigation aims to determine if AFT offers similar reconstructive outcomes with potentially lower morbidity in this specific population.

Why it matters

Potential benefit: If successful, AFT could offer a less invasive option with comparable satisfaction and safety, potentially reducing complications and costs.

How similar studies have gone: Previous work in autologous reconstruction shows promise for AFT in selected patients, but direct non-inferiority data versus DIEP in irradiated breasts are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female, aged \>18 years.
* BMI between \> 22 and \<35 kg/m2
* History of breast cancer treated with mastectomy (minimally 3 months after mastec-tomy) and post mastectomy chest wall radiotherapy (completed ≥6 months before en-rollment).
* May include contralateral/bilateral prophylactic mastectomy if at least one side had cancer and radiation.
* Desires autologous breast reconstruction and accepts randomization between AFT and DIEP.
* Medically fit for surgery (ASA I-III).
* Sufficient donor tissue for both AFT (enough fat) and DIEP (suitable abdominal tissue and vasculature).
* No evidence of active cancer at enrollment; remission confirmed.
* Able to wear the EVE device (if randomized in AFT).
* Capable of understanding study information and questionnaires (Dutch or English), willing to give informed consent, and able to comply with follow-up.

Exclusion Criteria:

* Prior autologous breast reconstruction on the intended side. BMI \<22 or \>35 kg/m2
* Contraindication to DIEP flap (e.g., prior abdominoplasty or abdominal scars affecting perforators).
* Contraindication to AFT (e.g., insufficient fat or conditions impairing fat graft viability).
* Current chemotherapy or completed less than 4 weeks prior to enrollment.
* Serious uncontrolled comorbidities making elective surgery unsafe (e.g., unstable heart disease, severe coagulopathy, end-stage organ failure).
* Active smoker or not abstinent for at least 6 weeks pre-operatively.
* Pregnant at time of enrollment.
* In case low compliance is expected or an inability to comply with study protocol, including unwillingness to undergo either AFT or DIEP, or inability to complete follow-up (due to language, cognitive issues, or relocation plans).
* Previous enrollment in this trial (patients can only be included once, even if later presenting for contralateral reconstruction).
* Allergy to lidocaine or silicone

Where it's running

  • AzM
    Maastricht, Limburg, Netherlands
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.